Stockscreener 앱 받기
182.58
0.72%
1.30
시간 외 거래:
183.88
1.30
+0.71%
전일 마감가:
$181.28
열려 있는:
$181.82
하루 거래량:
1.34M
Relative Volume:
0.42
시가총액:
$52.33B
수익:
$20.87B
순이익/손실:
$1.50B
주가수익비율:
34.84
EPS:
5.24
순현금흐름:
$2.59B
1주 성능:
+2.42%
1개월 성능:
+7.58%
6개월 성능:
-24.07%
1년 성능:
-22.08%
1일 변동 폭
$181.54
$182.87
1주일 범위
$175.31
$182.87
52주 변동 폭
$163.33
$251.99
벡톤 디킨슨 Stock (BDX) Company Profile
명칭
Becton Dickinson Co
전화
(201) 847-6800
주소
ONE BECTON DR, FRANKLIN LAKES
BDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
182.58 | 51.96B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ISRG
Intuitive Surgical Inc
|
501.95 | 183.15B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
92.22 | 43.85B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
273.37 | 39.21B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
227.31 | 15.73B | 2.90B | 467.20M | 306.90M | 6.37 |
벡톤 디킨슨 Stock (BDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-05-02 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-05-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-05-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Sell → Neutral |
| 2022-07-11 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2022-06-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | 재개 | Raymond James | Mkt Perform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2021-12-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-25 | 개시 | Barclays | Equal Weight |
| 2020-12-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-06-01 | 재개 | Goldman | Buy |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-07 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-02-07 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-01-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-05-13 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-12-07 | 개시 | Deutsche Bank | Buy |
| 2018-10-16 | 개시 | Barclays | Equal Weight |
| 2018-06-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-04-10 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-01-19 | 재개 | BofA/Merrill | Buy |
| 2018-01-05 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-01-05 | 개시 | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2017-12-29 | 재확인 | Deutsche Bank | Buy |
모두보기
벡톤 디킨슨 주식(BDX)의 최신 뉴스
Becton, Dickinson and Company (BDX) Fell in Q2 as Earnings Fell Short of Expectations - Insider Monkey
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs – Company AnnouncementFT.com - Financial Times
Becton Dickinson & Co To Go Ex-Dividend On September 8th, 2025 With 1.04 USD Dividend Per Share - 富途牛牛
Becton Dickinson Investors Seek Final OK Of $9M Deal - Law360
What drives Becton Dickinson and Company stock priceBreakthrough financial growth - jammulinksnews.com
Becton Dickinson & Co Slips to 346th in Trading Volume Despite 3.39% Stock Price Gain - AInvest
Jim Cramer Notes Becton Dickinson Stock Recently “Finished in the Black” - MSN
Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal - MSN
The Smartest Dividend Stock to Buy With $1,000 Right Now - The Motley Fool
Vascular Access Devices Company Evaluation Report 2025 | Becton Dickinson, Teleflex, and ICU Medical Strengthen Global Leadership Through Strategic Acquisitions and Product Innovation - Yahoo Finance
BD issues voluntary recall on certain Alaris infusion pump modules - MassDevice
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Announces Target Price $190 - 富途牛牛
Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX) - 富途牛牛
Morgan Stanley Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $196 - 富途牛牛
BD issues update to recall of Alaris & BD Alaris pump modules - MarketScreener
BD to spin off biosciences, diagnostics businesses in $17.5B deal (updated) - NJBIZ
Waters to acquire BD flow cytometry business in a deal valued at $17.5 billion - C&EN
Becton Dickinson and : BD Issues Update to Voluntary Global Recall of Alaris™ and BD Alaris™ Pump Modules Serviced with Legacy Bezel Kit Assemblies - MarketScreener
How Do Investors Really Feel About Becton Dickinson? - 富途牛牛
Becton Dickinson stock holds steady as TD Cowen maintains $183 price target By Investing.com - Investing.com South Africa
Becton Dickinson stock holds steady as TD Cowen maintains $183 price target - Investing.com Nigeria
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Becton, Dickinson and Company (BDX) Traded Down on Weak Earnings - Insider Monkey
Becton, Dickinson and Company: A Solid Divestment For Its Bioscience And Diagnostics Business - Seeking Alpha
Becton Dickinson’s Hold Rating Amid Strategic Moves and Limited Immediate Upside - TipRanks
TD Cowen Initiates Becton Dickinson & Co(BDX.US) With Hold Rating, Announces Target Price $183 - 富途牛牛
Waters, BD’s Biosciences & Diagnostic Solutions to combine - Medical Buyer
A Big Move By Waters Corporation And Becton, Dickinson And Company (NYSE:WAT) - Seeking Alpha
William Blair Maintains Becton Dickinson & Co(BDX.US) With Hold Rating - 富途牛牛
BD’s biosciences & diagnostics unit in $17.5B merger with Waters - BioWorld MedTech
$17.5B Deal Combines Waters with BD’s Biosciences and Diagnostics Business - Genetic Engineering and Biotechnology News
Becton Dickinson Announces Reverse Morris Trust with Waters - TipRanks
Becton Dickinson Finds a Partner for Its Biosciences and Diagnostics Business in Waters - Morningstar
Milford’s Waters Corp. strikes $17.5 billion deal to merge with BD’s diagnostics unit - The Boston Globe
Waters to buy Becton Dickinson unit in a $17.5 billion deal amid tariff pressures - CNBC
Waters, BD Unite in $17.5B Diagnostics Deal - USA Herald
Waters, BD Biosciences & Diagnostic Solutions to combine in $17.5B deal - MassDevice
Analytics Equipment Maker Waters Buys Becton Dickinson Unit in a $17.5B Deal - Investopedia
Waters inks $17.5B merger with division of BD - The Business Journals
Becton Dickinson Spins Off Biosciences In $17.5 Billion Waters Deal - Finimize
Here’s Why Becton, Dickinson and Company (BDX) Traded Lower in Q2 - MSN
Waters, BD Biosciences & Diagnostic Solutions to Merge in $17.5B Deal - Medical Product Outsourcing
Becton Dickinson gets its spinoff deal, but the stock is still falling - MSN
Why is Waters Stock Down On Monday?Becton Dickinson (NYSE:BDX), Waters (NYSE:WAT) - Benzinga
Becton, Dickinson and Company (BDX) Announces Strategic Merger w - GuruFocus
Waters and BD’s Biosciences & Diagnostic Solutions Business To Merge - citybiz
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing - Placera.se
Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal - MarketScreener
Waters to Create $6.5B Life Sciences Giant Through $17.5B Merger with BD Biosciences Division - Stock Titan
Becton, Dickinson and Co. Advances with SiteRite 9 Ultrasound System Study - TipRanks
BD to acquire Bard - The Covington News
벡톤 디킨슨 (BDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
벡톤 디킨슨 주식 (BDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Garrison Michael David | EVP & President, Medical |
Jul 18 '25 |
Sale |
180.29 |
1,185 |
213,645 |
4,887 |
4.02%
자본화:
|
볼륨(24시간):